骨髓增殖性肿瘤与冠心病
|
摘要
骨髓增殖性肿瘤是动脉粥样硬化和动脉栓塞的高危风险因素。文章主要对骨髓增殖性肿瘤与冠心病在其发病情况、病理机制、临床特点及诊疗方面进行综述,强调骨髓增殖性肿瘤作为冠心病患者发生不良心血管事件潜在风险因素的重要性,帮助临床医师理解和诊治相关疾病。
Myeloproliferative neoplasms(MPN) are high risk factors of atherosclerosis and arterial thromboembolism. This article gives a review on the incidence, pathogenesis, clinical features and treatment of MPN with coronary artery disease, emphasizing the importance of knowing MPN as possible causes of acute cardiovascular events in patients, in order to help clinicians to learn about the disease and make a proper diagnosis and treatment.
Myeloproliferative neoplasms(MPN) are high risk factors of atherosclerosis and arterial thromboembolism. This article gives a review on the incidence, pathogenesis, clinical features and treatment of MPN with coronary artery disease, emphasizing the importance of knowing MPN as possible causes of acute cardiovascular events in patients, in order to help clinicians to learn about the disease and make a proper diagnosis and treatment.
引文
[1]Mascarenhas J. Concise Update on Risk Factors, Therapy, and Outcome of Leukemic Transformation of Myeloproliferative Neoplasms[J]. Clin Lymphoma Myeloma Leuk, 2016, 16(Suppl):S124-129.
[2]Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia[J]. Blood, 2016, 127(20):2391-2405.
[3]张晟瑜.骨髓增殖性肿瘤患者并发急性冠脉综合征相关因素分析[J].基础医学与临床, 2015, 4(35):514-517.
[4]董焕.骨髓增殖性肿瘤血栓形成的研究进展[J].国际输血及血液学杂志, 2017, 6(40):508-511.
[5]Moulard O, Mehta J, Fryzek J, et al. Epidemiology of myelofibrosis,essential thrombocythemia, and polycythemia vera in the European Union[J]. Eur J Haematol, 2014, 92(4):289-297.
[6]Mele M, Vigna C, Villella A.[Very late coronary drug-eluting stent thrombosis in a patient with essential thrombocythemia:a case report of a rare association][J]. G Ital Cardiol(Rome), 2012, 13(7-8):520-522.
[7]PosfaiE,MartonI,BorbenyiZ,etal.Myocardialinfarctionas athromboticcomplicationofessentialthrombocythemiaand polycythemia vera[J]. Anatol J Cardiol, 2016, 16(6):397-402.
[8]Muendlein A, Gasser K, Kinz E, et al. Evaluation of the prevalence and prospective clinical impact of the JAK2 V617F mutation in coronary patients[J]. Am J Hematol, 2014, 89(3):295-301.
[9]Hasselbalch HC, Bjorn ME. MPNs as Inflammatory Diseases:The Evidence, Consequences, and Perspectives[J]. Mediators Inflamm,2015, 2015:102476.
[10]Inami T, Okabe M, Matsushita M, et al. JAK2 mutation and acute coronarysyndromecomplicatedwithstentthrombosis[J].Heart Vessels, 2016, 31(10):1714-1716.
[11]Skoda RC, Duek A, Grisouard J. Pathogenesis of myeloproliferative neoplasms[J]. Exp Hematol, 2015, 43(8):599-608.
[12]Jaeger T, Muendlein A, Hodaie J, et al. Prevalence of calreticulin exon9 indel mutations in vascular risk patients[J]. Thromb Res, 2016, 144:215-217.
[13]BarbuiT,FalangaA.Molecularbiomarkersofthrombosisin myeloproliferative neoplasms[J]. Thromb Res, 2016, 140(Suppl 1):S71-75.
[14]Nahler A, Fuchs D, Reiter C, et al. Myocardial infarction with proximal occlusion of the left anterior descending coronary artery in a 22-yearoldpatientwithpolycythaemiavera[J].ClinMed(Lond),2017,17(1):46-47.
[15]Osada H, Nakajima H, Meshii K, et al. Acute coronary artery bypass graft failure in a patient with polycythemia vera[J]. Asian Cardiovasc Thorac Ann, 2016, 24(2):175-177.
[16]SinglaA,JagasiaD,GargM,etal.AcuteST-segmentelevation myocardialinfarction:arareinitialpresentationofpreviously undiagnosed essential thrombocythemia[J]. Platelets, 2012, 23(6):463-466.
[17]Xiong N, Gao W, Pan J, et al. Essential thrombocythemia presenting as acute coronary syndrome:case reports and literature review[J]. J Thromb Thrombolysis, 2017, 44(1):57-62.
[2]Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia[J]. Blood, 2016, 127(20):2391-2405.
[3]张晟瑜.骨髓增殖性肿瘤患者并发急性冠脉综合征相关因素分析[J].基础医学与临床, 2015, 4(35):514-517.
[4]董焕.骨髓增殖性肿瘤血栓形成的研究进展[J].国际输血及血液学杂志, 2017, 6(40):508-511.
[5]Moulard O, Mehta J, Fryzek J, et al. Epidemiology of myelofibrosis,essential thrombocythemia, and polycythemia vera in the European Union[J]. Eur J Haematol, 2014, 92(4):289-297.
[6]Mele M, Vigna C, Villella A.[Very late coronary drug-eluting stent thrombosis in a patient with essential thrombocythemia:a case report of a rare association][J]. G Ital Cardiol(Rome), 2012, 13(7-8):520-522.
[7]PosfaiE,MartonI,BorbenyiZ,etal.Myocardialinfarctionas athromboticcomplicationofessentialthrombocythemiaand polycythemia vera[J]. Anatol J Cardiol, 2016, 16(6):397-402.
[8]Muendlein A, Gasser K, Kinz E, et al. Evaluation of the prevalence and prospective clinical impact of the JAK2 V617F mutation in coronary patients[J]. Am J Hematol, 2014, 89(3):295-301.
[9]Hasselbalch HC, Bjorn ME. MPNs as Inflammatory Diseases:The Evidence, Consequences, and Perspectives[J]. Mediators Inflamm,2015, 2015:102476.
[10]Inami T, Okabe M, Matsushita M, et al. JAK2 mutation and acute coronarysyndromecomplicatedwithstentthrombosis[J].Heart Vessels, 2016, 31(10):1714-1716.
[11]Skoda RC, Duek A, Grisouard J. Pathogenesis of myeloproliferative neoplasms[J]. Exp Hematol, 2015, 43(8):599-608.
[12]Jaeger T, Muendlein A, Hodaie J, et al. Prevalence of calreticulin exon9 indel mutations in vascular risk patients[J]. Thromb Res, 2016, 144:215-217.
[13]BarbuiT,FalangaA.Molecularbiomarkersofthrombosisin myeloproliferative neoplasms[J]. Thromb Res, 2016, 140(Suppl 1):S71-75.
[14]Nahler A, Fuchs D, Reiter C, et al. Myocardial infarction with proximal occlusion of the left anterior descending coronary artery in a 22-yearoldpatientwithpolycythaemiavera[J].ClinMed(Lond),2017,17(1):46-47.
[15]Osada H, Nakajima H, Meshii K, et al. Acute coronary artery bypass graft failure in a patient with polycythemia vera[J]. Asian Cardiovasc Thorac Ann, 2016, 24(2):175-177.
[16]SinglaA,JagasiaD,GargM,etal.AcuteST-segmentelevation myocardialinfarction:arareinitialpresentationofpreviously undiagnosed essential thrombocythemia[J]. Platelets, 2012, 23(6):463-466.
[17]Xiong N, Gao W, Pan J, et al. Essential thrombocythemia presenting as acute coronary syndrome:case reports and literature review[J]. J Thromb Thrombolysis, 2017, 44(1):57-62.